Riskpilot← Back to searchSign inGet full accessVITALIS PHARMA AS
ASActiveOrg 989453750Drengsrudhagen 6, 1385 AskerWholesale of pharmaceutical and medical goods · NACE 4646Est. 200635 employees
Revenue 2024
NOK 151,4M
+20% vs 2023
EBITDA margin
25.1%
+104% vs 2023
Equity ratio
5.8%
Financial strength
Net profit 2024
NOK 28,5M
+115% vs 2023
| Revenue | NOK 151,4M | +20% |
| EBITDA | NOK 38,1M | +104% |
| Net profit | NOK 28,5M | +115% |
| Total assets | NOK 62M | -18% |
| Equity | NOK 3,6M | +444% |
| Employees | 35 | — |
Legal name
VITALIS PHARMA AS
Org number
989453750
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
14. februar 2006
Share capital
NOK 300 048
Employees
35 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder eller styrets leder hver for seg.
Company purpose
Handel med helseartikler samt hva hermed står i forbindelse, herunder å delta i andre foretagender med tilsvarende virksomhet.
Address
Drengsrudhagen 6, 1385 Asker
Phone
+4745035598
Email
admin@vitalispharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 100 019 | 99 054 | 103 832 | 125 713 | 151 434 |
| Staff expenses | −2 867 | −3 640 | −3 344 | −4 004 | −12 594 |
| EBITDA | 21 531 | 17 077 | 27 159 | 18 687 | 38 074 |
| Depreciation & amort. | −7 | −17 | −20 | −1 040 | −1 711 |
| EBIT | 21 524 | 17 060 | 27 139 | 17 648 | 36 363 |
| Net financials | −284 | 112 | −18 | −684 | −444 |
| Profit before tax | 21 240 | 17 173 | 27 120 | 16 964 | 35 919 |
| Tax | 4 670 | 3 803 | 6 527 | 3 699 | 7 373 |
| Net profit | 16 570 | 13 370 | 20 594 | 13 265 | 28 546 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 48 286 | 56 905 | 42 487 | 75 984 | 61 956 |
| Equity | 378 | 2 553 | 516 | 665 | 3 619 |
| Long-term debt | 17 002 | 23 336 | 34 361 | 46 355 | 48 772 |
| Short-term debt | 30 907 | 31 016 | 7 610 | 28 964 | 9 565 |
| Total debt | 47 908 | 54 352 | 41 971 | 75 320 | 58 337 |
EBITDA margin
25.1%
This company
15.8%
Market median
+59% vs market
20202024
Equity ratio
5.8%
This company
38.2%
Market median
-85% vs market
20202024
Return on equity
788.9%
This company
18.4%
Market median
+4188% vs market
20202024
Net profit margin
18.9%
This company
8.1%
Market median
+133% vs market
20202024
Asset turnover
2.44×
This company
1.12×
Market median
+118% vs market
20202024
Debt / equity
16.12×
This company
0.62×
Market median
-2500% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
YZ Chief Executive Officer | Chief Executive Officer | 2006 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2018 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Norsund Gruppen As
VITALIS PHARMA AS Board members of VITALIS PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Yunlin Zhan | Chief Executive Officer | 0 companies |
| Vegard Moltubakk | Chairman | 0 companies |